Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05196035




Registration number
NCT05196035
Ethics application status
Date submitted
7/01/2022
Date registered
19/01/2022
Date last updated
5/09/2024

Titles & IDs
Public title
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Scientific title
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria
Secondary ID [1] 0 0
2023-504884-17-00
Secondary ID [2] 0 0
19920
Universal Trial Number (UTN)
Trial acronym
FIONA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Disease 0 0
Proteinuria 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Finerenone (Kerendia, BAY94-8862)
Treatment: Drugs - Placebo

Experimental: Finerenone (Kerendia, BAY94-8862) - Participants will receive finerenone treatment.

Placebo comparator: Placebo - Participants will receive placebo to finerenone.


Treatment: Drugs: Finerenone (Kerendia, BAY94-8862)
Finerenone in different doses, treatment duration will be 180±7 days

Treatment: Drugs: Placebo
Placebo to finerenone, treatment duration will be 180±7 days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Urinary protein-to-creatinine ratio (UPCR) reduction of at least 30% from baseline to day 180±7
Timepoint [1] 0 0
From baseline to day 180±7
Secondary outcome [1] 0 0
Number participants with treatment emergent adverse events (TEAEs)
Timepoint [1] 0 0
From the start of study intervention to last study intervention + 3 days (up to 190 days)
Secondary outcome [2] 0 0
Change in serum potassium levels from baseline to day 180±7
Timepoint [2] 0 0
From baseline to day 180±7
Secondary outcome [3] 0 0
Change in serum creatinine from baseline to day 180±7
Timepoint [3] 0 0
From baseline to day 180±7
Secondary outcome [4] 0 0
Change in eGFR from baseline to day 180±7
Timepoint [4] 0 0
From baseline to day 180±7
Secondary outcome [5] 0 0
Change in systolic blood pressure from baseline to day 180±7
Timepoint [5] 0 0
From baseline to day 180±7
Secondary outcome [6] 0 0
Mean reduction from baseline to day 180±7 in UPCR
Timepoint [6] 0 0
From baseline to day 180±7
Secondary outcome [7] 0 0
Change in UACR from baseline to day 180±7
Timepoint [7] 0 0
From baseline to day 180±7
Secondary outcome [8] 0 0
Pharmacokinetics (PK) finerenone Cmax, md
Timepoint [8] 0 0
Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7
Secondary outcome [9] 0 0
Pharmacokinetics (PK) finerenone AUCt,md
Timepoint [9] 0 0
Pre-dose, post-dose (1.5-5 hours after intake of intervention), up to day 180±7
Secondary outcome [10] 0 0
Taste and texture questionnaire of the pediatric formulation
Timepoint [10] 0 0
On day 30±3 and day 180±7

Eligibility
Key inclusion criteria
* Participants must be 6 months to <18 years old at the time when the informed consent/assent is signed
* Participants must have a clinical diagnosis of chronic kidney disease (CKD) at screening which is defined as

* CKD stages 1-3 (eGFR =30 mL/min/1.73m^2) for children =1 year to <18 years of age or
* a serum creatinine = 0.40 mg/dL for infants 6 months to < 1 year of age and
* severely increased proteinuria as defined by

* Urinary protein-to-creatinine ratio (UPCR) of = 0.50 g/g in participants = 2 years with CKD stage 2 and 3 or
* UPCR = 1.0 g/g for patients < 2 years of age or = 2 years of age and with CKD stage 1
* Participants must have stable kidney function between screening and D0 defined as:

* For participants with a creatinine of > 0.8 mg/dL at screening: no increase or decrease in eGFR by = 20% at D0
* For participants with a creatinine of = 0.8 mg/dL at screening: no increase or decrease in creatinine = 0.15 mg/dL at D0.
* Treated with an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at optimized doses defined as maximally tolerable doses within the recommended dose range according to guidelines on blood pressure management, unchanged for at least 30 days prior to screening
* K+ =5.0 mmol/L for children =2 years of age at both screening and D0, and =5.3 mmol/L for children <2 years of age at both screening and D0
Minimum age
6 Months
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Planned urological surgery expected to influence renal function
* Children with hemolytic uremic syndrome (HUS) diagnosed =6 months prior to screening
* Patients with nephrotic syndrome receiving albumin infusions within the last 6 months prior to screening
* Patients who are candidates for renal transplantation, i.e., a kidney transplantation scheduled within the study time frame
* Renal allograft in place
* Bilateral renal artery stenosis
* Acute kidney injury requiring dialysis within 6 months prior to screening
* Systemic hypertension stage 2 in children =1 year of age defined according to guidelines on blood pressure management at screening or randomization
* Systolic blood pressure (SBP) above 110 mmHg in infants 6 months to <1 year of age at screening or randomization
* Systemic hypotension defined as a systolic blood pressure below the 5th percentile for age, sex and height at either screening or randomization but no lower than 80 mmHg (although for some participants the 5th percentile of SBP is < 80 mmHg they must be excluded if their SBP is <80 mmHg)
* Participants with immune-mediated CKD using rituximab, cyclophosphamide, abatacept, or high-dose glucocorticoids, within <6 months prior to screening

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/03/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
11/03/2027
Actual
Sample size
Target
219
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [2] 0 0
Monash Children's Hospital - Clayton
Recruitment hospital [3] 0 0
Royal Children's Hospital Melbourne - Parkville
Recruitment postcode(s) [1] 0 0
4101 - South Brisbane
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
District of Columbia
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Missouri
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Utah
Country [12] 0 0
United States of America
State/province [12] 0 0
Washington
Country [13] 0 0
Argentina
State/province [13] 0 0
Ciudad Auton. De Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Provincia De San Luis
Country [15] 0 0
Argentina
State/province [15] 0 0
Provincia De Santa Fe
Country [16] 0 0
Argentina
State/province [16] 0 0
Buenos Aires
Country [17] 0 0
Austria
State/province [17] 0 0
Oberösterreich
Country [18] 0 0
Austria
State/province [18] 0 0
Steiermark
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Austria
State/province [20] 0 0
Wien
Country [21] 0 0
Belgium
State/province [21] 0 0
Bruxelles - Brussel
Country [22] 0 0
Belgium
State/province [22] 0 0
Gent
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Canada
State/province [25] 0 0
Alberta
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
Czechia
State/province [28] 0 0
Praha 2
Country [29] 0 0
Czechia
State/province [29] 0 0
Praha 5
Country [30] 0 0
Denmark
State/province [30] 0 0
Copenhagen
Country [31] 0 0
Denmark
State/province [31] 0 0
Odense C
Country [32] 0 0
Denmark
State/province [32] 0 0
Århus N
Country [33] 0 0
Finland
State/province [33] 0 0
Helsinki
Country [34] 0 0
Finland
State/province [34] 0 0
Tampere
Country [35] 0 0
Finland
State/province [35] 0 0
Turku
Country [36] 0 0
France
State/province [36] 0 0
BORDEAUX cedex
Country [37] 0 0
France
State/province [37] 0 0
Bron
Country [38] 0 0
France
State/province [38] 0 0
Montpellier
Country [39] 0 0
France
State/province [39] 0 0
Paris
Country [40] 0 0
France
State/province [40] 0 0
Strasbourg
Country [41] 0 0
France
State/province [41] 0 0
TOULOUSE Cedex 9
Country [42] 0 0
Germany
State/province [42] 0 0
Baden-Württemberg
Country [43] 0 0
Germany
State/province [43] 0 0
Niedersachsen
Country [44] 0 0
Germany
State/province [44] 0 0
Nordrhein-Westfalen
Country [45] 0 0
Germany
State/province [45] 0 0
Berlin
Country [46] 0 0
Germany
State/province [46] 0 0
Hamburg
Country [47] 0 0
Greece
State/province [47] 0 0
Athens
Country [48] 0 0
Greece
State/province [48] 0 0
Heraklion
Country [49] 0 0
Greece
State/province [49] 0 0
Ioannina
Country [50] 0 0
Greece
State/province [50] 0 0
Thessaloniki
Country [51] 0 0
Hungary
State/province [51] 0 0
Budapest
Country [52] 0 0
Hungary
State/province [52] 0 0
Debrecen
Country [53] 0 0
Hungary
State/province [53] 0 0
Pecs
Country [54] 0 0
Hungary
State/province [54] 0 0
Szeged
Country [55] 0 0
Israel
State/province [55] 0 0
Beer Sheva
Country [56] 0 0
Israel
State/province [56] 0 0
Jerusalem
Country [57] 0 0
Israel
State/province [57] 0 0
Nahariya
Country [58] 0 0
Israel
State/province [58] 0 0
Petach Tikva
Country [59] 0 0
Israel
State/province [59] 0 0
Tel Aviv
Country [60] 0 0
Italy
State/province [60] 0 0
Emilia-Romagna
Country [61] 0 0
Italy
State/province [61] 0 0
Lazio
Country [62] 0 0
Italy
State/province [62] 0 0
Liguria
Country [63] 0 0
Italy
State/province [63] 0 0
Lombardia
Country [64] 0 0
Italy
State/province [64] 0 0
Firenze
Country [65] 0 0
Italy
State/province [65] 0 0
Torino
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Daegu Gwang''yeogsi
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Gyeonggido
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Gyeongsangnamdo
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Seoul Teugbyeolsi
Country [70] 0 0
Lithuania
State/province [70] 0 0
Kaunas
Country [71] 0 0
Lithuania
State/province [71] 0 0
Klaipeda
Country [72] 0 0
Lithuania
State/province [72] 0 0
Vilnius
Country [73] 0 0
Netherlands
State/province [73] 0 0
Groningen
Country [74] 0 0
Netherlands
State/province [74] 0 0
Utrecht
Country [75] 0 0
Poland
State/province [75] 0 0
Bialystok
Country [76] 0 0
Poland
State/province [76] 0 0
Gdansk
Country [77] 0 0
Poland
State/province [77] 0 0
Lodz
Country [78] 0 0
Poland
State/province [78] 0 0
Warszawa
Country [79] 0 0
Portugal
State/province [79] 0 0
Braga
Country [80] 0 0
Portugal
State/province [80] 0 0
Porto
Country [81] 0 0
Spain
State/province [81] 0 0
Barcelona
Country [82] 0 0
Spain
State/province [82] 0 0
Madrid
Country [83] 0 0
Spain
State/province [83] 0 0
Málaga
Country [84] 0 0
Spain
State/province [84] 0 0
Sevilla
Country [85] 0 0
Sweden
State/province [85] 0 0
Lund
Country [86] 0 0
Sweden
State/province [86] 0 0
Stockholm
Country [87] 0 0
Switzerland
State/province [87] 0 0
Basel-Stadt
Country [88] 0 0
Switzerland
State/province [88] 0 0
Vaud
Country [89] 0 0
Switzerland
State/province [89] 0 0
Geneva
Country [90] 0 0
Turkey
State/province [90] 0 0
Adana
Country [91] 0 0
Turkey
State/province [91] 0 0
Ankara
Country [92] 0 0
Turkey
State/province [92] 0 0
Istanbul
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Glasgow
Country [94] 0 0
United Kingdom
State/province [94] 0 0
London
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Manchester
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine.

The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system.

The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB.

So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function.

The main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications.

To see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests.

This study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take:

* either finerenone or the placebo, in addition to
* either ACEI or ARB, whichever they take as part of their normal treatment

Two visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will:

* have their blood pressure, heart rate, temperature, height and weight measured
* have blood and urine samples taken
* have physical examinations
* have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart)
* answer questions about their medication and whether they have any adverse events , or have their parents or guardians answer
* answer questions about how they are feeling, or have their parents or guardians answer
* answer question about how they like the study medication, or have their parents or guardians answer

The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

The doctors will check the participants' health about 30 days after the participants take their last treatment.
Trial website
https://clinicaltrials.gov/study/NCT05196035
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Bayer Clinical Trials Contact
Address 0 0
Country 0 0
Phone 0 0
(+) 1-888-84 22937
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05196035